CLSA analysts upgraded Aurobindo Pharma (NSE:ARBN) (ARBP:IN) stock rating from Hold to Outperform, despite reducing the price target to INR1,400 from INR1,540. The revision reflects a modified ...

Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Today’s stock recommendations feature a mix of picks from the pharmaceutical, insurance, and chemicals sectors.

Aurobindo also has the highest contribution from the exports market among Indian pharma companies, and a depreciating rupee ...

Aurobindo Pharma Ltd.'s share price logging 14.6% fall in the last six months has driven Investec to initiate a 'fast long' on the stock, as it sees a depreciating rupee scenario to benefit, given its ...

Aurobindo Pharma stock dipped to 1,100 levels before rebounding, aligning with a channel line from October 2016’s swing high on monthly charts. The stock trades above 5, 10, 30, 50, and 200-DMA but ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Aurobindo Pharma Ltd share price was down by -1.25% from the previous closing price of ₹1,202.05. Who are peers of Aurobindo Pharma Ltd? The peers of Aurobindo Pharma Ltd are Sun Pharmaceuticals ...

Aurobindo Pharma Ltd is quoting at Rs 1197.8, up 1.65% on the day as on 12:49 IST on the NSE. The stock is up 5.66% in last one year as compared to a 9.94% jump in NIFTY and a 26.31% jump in the Nifty ...